We use essential cookies and third-party cookies for content.

Pallade Veneta - Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

HEALTH 20.06.2023
Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property
Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics

Change text size:

Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors

OXFORD, United Kingdom, June 20, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform, including all intellectual property rights therein, as well as secured exclusive access to certain engineering and manufacturing rights associated with it. This technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralizing antibodies.

“We are pleased to now own this technology and look forward to applying it in future exosome AAV programs. This acquisition further adds to our dominant intellectual property portfolio of patents that cover key aspects needed to develop and commercialise exosome therapeutics including their design, composition, and manufacture,” said Per Lundin, Ph.D., Chief Business Officer & Co-Founder of Evox Therapeutics. “This is part of our long-term business strategy of leveraging improved exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”.

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, to develop an entirely new class of therapeutics for the treatment of severe rare diseases. Evox uses its proprietary DeliverEX® technology to engineer exosomes to facilitate drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is backed by leading life sciences venture capital groups including Redmile and OrbiMed, and is supported by a comprehensive intellectual property portfolio.

For enquiries, please contact:

Media:
Simon Conway / Natalie Garland-Collins
[email protected]
+44 (0) 203 727 1000

Evox:
Dr. Antonin de Fougerolles, CEO
[email protected] 
+44 (0) 1865 819140

For further information visit: www.evoxtherapeutics.com


Primary Logo

B.Cretella--PV

Featured

Seacliff Healthcare Seeks Specialist GP in Thirroul

Seacliff Healthcare, located in the Illawarra region of New South Wales, is seeking a Specialist General Practitioner to join its team. The practice, situated near Thirroul village station, currently supports five GPs and has capacity for additional medical staff with onsite pathology and allied health services.

India proposes more import entry points for drugs and medical devices

New Delhi The Union Health Ministry has proposed expanding the network of authorised import gateways for drugs, medical devices and cosmetics by adding several inland container depots, a special economic zone and an international airport to facilitate faster clearance and improve supply chain efficiency. The proposed amendment to Rule 43A of the Drugs Rules, 1945, seeks to include additional entry points in Haryana, Uttar Pradesh, Gujarat, Telangana and Karnataka, as reported by a gazette notification issued by the

Why Pregnancy Cost Estimates Fail: A Family’s $9,000 Surprise

Grace Griffin thought she had calculated her pregnancy expenses accurately until bills exceeded $9,000—more than triple her insurer’s estimate. Her experience highlights a systemic failure in healthcare transparency, as federal rules designed to provide accurate cost predictions remain unimplemented. With maternity billing codes set to change next year, experts urge parents to master insurance details and verify every bill.

Kuwait inspectors destroy 115 kilograms of unverified meat in Farwaniya

KUWAIT: The Public Authority for Food and Nutrition (PAFN) issued nine violation reports and destroyed 115 kilograms of meat of unknown origin during an inspection tour of food establishments in Farwaniya Governorate, the authority announced on Monday. The tour was carried out by the authority’s Farwaniya food inspection department.

Change text size: